1-5 of 5
avert trial
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Enhanced VTE Risk Stratification in Ambulatory Patients with Cancer

Joseph R. Shaw, MD, Ranjeeta Mallick, PhD MSc, BSc, Marc Carrier, MD, Anton Ilich, MD, Nigel S. Key, MBChB, FRCP, Philip S. Wells, MDMSc,FRCP
Journal: Blood
Blood (2019) 134 (Supplement_1): 634.
https://doi.org/10.1182/blood-2019-126306
Published: 2019
Journal Articles

Thromboprophylaxis for Patients with Newly Diagnosed Vs. Recurrent Cancers: A Post-Hoc Analysis of the Avert Trial

Marina Atalla, James Zhang, MD, Ranjeeta Mallick, PhD MSc, BSc, Philip S. Wells, MDMSc,FRCP, Marc Carrier, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3660.
https://doi.org/10.1182/blood-2019-122970
Published: 2019
Journal Articles

Safety and Efficacy of Apixaban Thromboprophylaxis in Cancer Patients with Metastatic Disease: A Subgroup Analysis of the Avert Trial

William Knoll, BSc, Ranjeeta Mallick, PhD MSc, BSc, Philip S. Wells, MDMSc,FRCP, Marc Carrier, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1140.
https://doi.org/10.1182/blood-2019-128834
Published: 2019
Journal Articles

Cost-Utility Analysis of Apixaban Compared to Usual Care for the Primary Thromboprophylaxis of Ambulatory Cancer Patients Initiating Chemotherapy

Miriam Kimpton, MD, Srishti Kumar, MSc, Philip S. Wells, MDMSc,FRCP, Marc Carrier, MD, Kednapa Thavorn, MPharm, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 329.
https://doi.org/10.1182/blood-2019-127286
Published: 2019
Journal Articles

Real World Application of Thromboprophylaxis in Patients with Malignancy

Nicole Mischler, Nancy Fisher, MBA, Susan Frankii, MS, Attila J Kovacs, PhD, Lori Rosenstein, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3394.
https://doi.org/10.1182/blood-2019-131383
Published: 2019